INV724 / Invenra - LARVOL DELTA

Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment (Businesswire) - "Invenra Inc. is pleased to announce that its innovative bispecific antibody, INV724, developed for the treatment of neuroblastoma, has been awarded both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations by the U.S. Food and Drug Administration (FDA). These designations provide strategic advantages, including accelerated development, cost reductions, and financial incentives, further driving the advancement of groundbreaking therapies for rare pediatric diseases."

FDA event • Orphan drug • Neuroblastoma • Oncology • Solid Tumor